DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "US Tardive Dyskinesia Market: Size, Trends & Forecasts (2016-2025)" report to their offering.
This report provides analysis of the US tardive dyskinesia market, with detailed analysis of market size and growth, penetration, market share and economic impact of the industry. The report also provides the analysis of the major drugs (both existing and in pipeline) analysis, by penetrations, by revenue, etc.
Furthermore, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall US tardive dyskinesia market has been forecasted for the years 2016-2025, taking into consideration the previous growth pattern, the growth drivers and the current and future trends.
Tardive dyskinesia has many different treatments, including vitamin E, benzodiazepines, levodopa, reserpine, botullinum toxin, tetrabenazine, dopamine-depleting agents, and calcium channel blockers. Along with these, two new treatments are in the pipeline: Valbenazine and SD-809.
The US tardive dyskinesia market is expected to increase at a significant growth rate during the forecasted period (2016-2025). The US tardive dyskinesia market is supported by various growth drivers, such as increase in number of schizophrenia patients, rising bipolar disorder patients, etc. Yet, the market faces certain challenges, such as, increased use of atypical antipsychotics, under-diagnosed market, side effects of drugs, etc.
Valeant Pharmaceuticals, Neurocrine Biosciences and Teva Pharmaceutical Industries are some of the key companies in the US tardive dyskinesia market. The company profiling of these companies has been done in the report, which includes business overview, financial overview and respective business strategies of the companies.
Key Topics Covered:
1. Executive Summary
3. US Market Analysis
4. Market Dynamics
5. Competitive Landscape
6. Company Profiling
- Neurocrine Biosciences
- Teva Pharmaceutical Industries
- Valeant Pharmaceuticals
For more information about this report visit http://www.researchandmarkets.com/research/s9v6hj/us_tardive